TScan Therapeutics (TCRX) TD Cowen 46th Annual Health Care Conference summary

Program overview and clinical progress

• Lead asset targets residual disease in heme malignancies post-allogeneic transplant, aiming to prevent relapse.

• Phase I data showed a hazard ratio of 0.5 for relapse-free survival, with long-term persistence of engineered T cells.

• FDA agreement reached on pivotal trial design, with study launch planned for Q2 and top-line readout expected by end of 2028.

• Commercial-ready manufacturing process reduces production time from 17 to 12 days and is more efficient.

• Cohort C with 10+ patients using the new process is fully enrolled, with data to be shared in Q2.

Market opportunity and expansion plans

• Initial addressable market for TSC-101 is 2,100 patients/year in the U.S., with a peak revenue estimate of over $1.4 billion.

• Global addressable market for TSC-101 is about 7,500 patients/year, expanding to 15,000/year with additional HLA-targeted products.

• Two new INDs cleared for HLA expansion, with further products in late-stage discovery.

• Potential to address up to 20,000 patients/year with future oncology and non-oncology indications.

• Product pricing expected to align with other cell therapies, estimated at $675,000 per treatment.

Clinical data and safety profile

• Phase I study included 23 treatment and 19 control patients, with balanced risk profiles.

• Product demonstrated a strong safety profile, with only mild and manageable adverse events.

• Most patients converted to MRD negative after first infusion, with improved donor chimerism in the treatment arm.

• Chimerism at two months is a strong predictor of long-term outcomes.

• Engineered T cells persist long-term in all tested patients.